COVAXIN shows interim efficacy of 81% against coronavirus in Phase 3 clinical trials, says Bharat Biotech
COVAXIN reveals interim efficacy of 81% in opposition to coronavirus in Part 3 scientific trials, says Bharat Biotech The primary interim evaluation is predicated on 43 circumstances, of which 36 circumstances of COVID-19 had been noticed within the placebo group versus seven circumstances noticed within the BBV152 (Covaxin) group, the corporate stated COVAXIN vaccine by… Read More »